Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

Wyeth is now a wholly owned subsidiary of Pfizer72 enrolled

Overview

The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens. It is an open label study with no placebo control or comparator drugs. Subjects will take one dose of the investigation formulation daily for 14 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Postmenopause

Interventions

Bazedoxifene/conjugated estrogensDRUG

Eligibility

Sex: FEMALEMin age: 40 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Postmenopausal women, aged 40 to 65 years. * Use of oral estrogen-, progestin-, or androgen-, or SERM-containing drug products within 8 weeks before screening. * A history or active presence of clinically relevant important medical disease.

Locations (1)

Unnamed facility

Gainesville, Florida, United States

Outcomes

Primary Outcomes

Pharmacokinetic analyses.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.